Randomised, Double-blind (Within Dose Groups), Placebo-controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Diabetic Kidney Disease
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Avenciguat (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 13 Jan 2023 This trial has been completed in Denmark (End Date: 27 Dec 2022) according to European Clinical Trials Database record.
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 28 Dec 2022 to 26 Dec 2022.